Log in

Relevant bibliographies by topics / Combination drug therapies / Books

Books on the topic 'Combination drug therapies'

To see the other types of publications on this topic, follow the link: Combination drug therapies.

Author: Grafiati

Published: 10 December 2022

Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 17 books for your research on the topic 'Combination drug therapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

L, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging., and International Symposium on Combination Therapies (2nd : 1992 : Acireale, Italy), eds. Combination therapies 2: Biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

L, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging., and International Symposium on Combination Therapies (1st : 1991 : Washington, D.C.), eds. Combination therapies: Biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Goldstein, Allan L., and E. Garaci. Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Goldstein, Allan L., and E. Garaci. Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer London, Limited, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Serpell, Mick G. Antineuropathic medication combination therapy. Edited by Paul Farquhar-Smith, Pierre Beaulieu, and Sian Jagger. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834359.003.0068.

Full text

Abstract:

The landmark paper discussed in this chapter is ‘Morphine, gabapentin, or their combination for neuropathic pain’, published by Gilron et al. in 2005. Although combination drug therapies for neuropathic pain had long been suggested, this seminal paper provided the first evidence for efficacy of combination therapy of mechanistically distinct medications in analgesia, using morphine in combination with gabapentin in post-herpetic neuralgia or diabetic neuropathy. Combination therapy had greater efficacy than gabapentin alone and was equally effective as morphine alone but with a lower dose of morphine; however, this did not seem to translate into reduced side effects. To this day, precious little is known about what are the most effective combinations for neuropathic pain, and the need for large randomized controlled trials in this area is still as pressing it was back in 2005.

APA, Harvard, Vancouver, ISO, and other styles

7

Mbabazi, Johnson. Combination of Drug Therapies Is Better Than Exercise Alone in Controlling HbA1c Levels Type 2 Diabetes Patients. Independently Published, 2019.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Goldstein, Allan L., and E. Garaci. Combination Therapies 2: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer London, Limited, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Combination Therapies 2: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Siebert, Stefan, Sengupta Raj, and Alexander Tsoukas. Non-pharmacological treatment of axial spondyloarthritis. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198755296.003.0014.

Full text

Abstract:

While drugs play a key role in reducing disease activity, non-pharmacological therapies are crucial in maintaining function, flexibility, and quality of life. Therefore, non-pharmacological therapy remains a key component in the optimal management of axial spondyloarthritis (axSpA), even in the era of biologics. Regular physical therapy allows patients to capitalize on the benefits of drug therapy and maintain optimal functional ability. Self-management and education strategies, supported by patient-support groups, facilitate independence and quality of life in chronic diseases. A proportion of patients with severe disease may require hip or spinal surgery. It is hoped that the availability of more effective drug therapies to control disease activity in axSpA will reduce the requirement for surgery in future. The optimal management of axSpA requires a combination of non-pharmacological and pharmacological treatments, for both initial and long-term management.

APA, Harvard, Vancouver, ISO, and other styles

11

Wenham, Claire Y. J., and Philip G. Conaghan. Osteoarthritis—management. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0140.

Full text

Abstract:

Osteoarthritis (OA) is a common condition which often causes pain and functional limitation, significantly impacting on a person's quality of life. A comprehensive assessment of the impact of OA should be performed before selecting therapies and treatment goals. Current recommended therapies include a combination of pharmacological and non-pharmacological therapies, which should be considered for all people with OA, regardless of anatomical site of involvement. Non-pharmacological treatments include education, muscle strengthening and aerobic exercises, weight loss if appropriate, splints and devices, and aids. Pharmacological therapies include paracetamol, oral and topical non-steroidal anti-inflammatory drugs, topical capsaicin, intra-articular corticosteroid injections, and opioids. Many existing therapies have only a small analgesic effect size and, in the case of drug therapies, may be associated with important side effects, so an individual's symptoms and comorbidities must be taken into account when selecting therapies. For those who do not respond to these treatments, surgery such as a total joint arthroplasty may be required. There is a strong need for new analgesic treatments for OA. As it is becoming increasingly clear that the sources of pain in OA are complex and multifactorial, future treatments for OA will need to target both peripheral and central pain mechanisms.

APA, Harvard, Vancouver, ISO, and other styles

12

Hammond, Alexis S., and Eric C. Strain. Current Approved Pharmacotherapies for Substance Use Disorders. Edited by Dennis S. Charney, Eric J. Nestler, Pamela Sklar, and Joseph D. Buxbaum. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190681425.003.0049.

Full text

Abstract:

About 3%–6% of the US population (an estimated 17 million people) were diagnosed with a substance use disorder (SUD) in 2014. This significant problem requires continued development of appropriate and effective therapies. Current treatments often include a combination of both pharmacologic and psychosocial modalities, tailored to an individual’s needs. This chapter provides a general overview of the pharmacotherapies that are currently approved by the US Food and Drug Administration for particular SUD indications. Those SUDs for which there are approved treatments include opioids, nicotine, and alcohol use disorders. Promising non-approved or investigational drugs are also briefly reviewed.

APA, Harvard, Vancouver, ISO, and other styles

13

Ledingham, Joanna, and Sarah Westlake. Immunosuppressants. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0080.

Full text

Abstract:

A variety of immunosuppressants and disease-modifying anti-rheumatic drugs (DMARDs) with beneficial effects on inflammatory rheumatic diseases have been identified over the last 50 years. Their use for these conditions is now well established and has led to considerable improvements in disease management. Their use earlier in the inflammatory disease process and the use of combination therapies have also led to significantly improved patient outcomes. This chapter provides an overview of the immunosuppressants and DMARDs used to treat rheumatic disease, focusing particularly on those in common use and with the best evidence for efficacy. The mechanism of action, toxicity, and clinical indications are outlined. Tips for practical prescribing and for monitoring for potential complications are also included.

APA, Harvard, Vancouver, ISO, and other styles

14

Ledingham, Joanna, and Sarah Westlake. Immunosuppressants. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199642489.003.0080_update_001.

Full text

Abstract:

A variety of immunosuppressants and disease-modifying anti-rheumatic drugs (DMARDs) with beneficial effects on inflammatory rheumatic diseases have been identified over the last 50 years. Their use for these conditions is now well established and has led to considerable improvements in disease management. Their use earlier in the inflammatory disease process and the use of combination therapies have also led to significantly improved patient outcomes. This chapter provides an overview of the immunosuppressants and DMARDs used to treat rheumatic disease, focusing particularly on those in common use and with the best evidence for efficacy. The mechanism of action, toxicity, and clinical indications are outlined. Tips for practical prescribing and for monitoring for potential complications are also included.

APA, Harvard, Vancouver, ISO, and other styles

15

United States. Congress. Senate. Committee on Appropriations. Subcommittee on Departments of Labor, Health and Human Services, Education, and Related Agencies, ed. HIV/AIDS drugs: Funding implications of new combination therapies for federal and state programs : report to the Subcommittee on Labor, Health and Human Services, and Education, Committee on Appropriations, U.S. Senate. Washington, D.C. (P.O. Box 37050, Washington 20013): The Office, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Deighton, Chris. Rheumatoid arthritis—management. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0112.

Full text

Abstract:

Influential guidelines on rheumatoid arthritis (RA) management agree on most key recommendations. Early diagnosis of persistent synovitis, and identification of poor prognostic markers, is essential. Rapid intervention is vital with drugs to suppress inflammation, slow down damaging disease components, and prevent disability. The label of RA covers a broad spectrum of disease severity, and there is controversy on: • whether the same interventions are needed for all patients • whether monotherapy or combination treatment is appropriate • the role of steroids in RA • the appropriate introduction of biological therapies. Treating to specified targets is optimal evidence-based practice, where patients are reviewed regularly for disease activity assessments, and inadequate control rectified. Aiming for remission is the ultimate goal, though for some patients minimal disease activity may be appropriate. Patient education addressing self-management is important, and the multidisciplinary team (MDT: specialist nurses, physiotherapists, occupational therapists, podiatrists, psychologists) needs to be involved from the start to minimize the impact on quality of life of the patient. For established disease, rapid access is important for flares, and to consider whether disease management could be improved. An intermittent overview of established disease is important with access to the MDT, and assessments for comorbidities such as ischaemic heart disease, osteoporosis, and depression, as well as complications of the disease itself such as cervical spine disease, vasculitis, and lung and eye complications. An informed patient needs to be central to all decision making.

APA, Harvard, Vancouver, ISO, and other styles

17

Elder, Grahame J. Metabolic bone disease after renal transplantation. Edited by Jeremy R. Chapman. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0288.

Full text

Abstract:

Patients who undergo kidney transplantation have laboratory, bone, and soft tissue abnormalities that characterize chronic kidney disease mineral and bone disorder (CKD-MBD). After successful transplantation, abnormal values of parathyroid hormone, fibroblast growth factor 23, calcium, phosphate, vitamin D sterols, and sex hormones generally improve, but abnormalities often persist. Cardiovascular risk remains high and is influenced by prevalent vascular calcification, and fracture risk increases due to a combination of abnormal bone ‘quality’, compounded by immunosuppressive drugs and reductions in bone mineral density. Patients with well managed CKD-MBD before transplantation generally have a smoother post-transplant course, and it is useful to assess patients soon after transplantation for risk factors relevant to the general population and to patients with CKD. Targeted laboratory assessment, bone densitometry, and X-ray of the spine are useful for guiding therapy to minimize post-transplant effects of CKD-MBD. To reduce fracture risk, general measures include glucocorticoid dose minimization, attaining adequate 25(OH)D levels, and maintaining calcium and phosphate values in the normal range. Calcitriol or its analogues and antiresorptive agents such as bisphosphonates may protect bone from glucocorticoid effects and ongoing hyperparathyroidism, but the efficacy of these therapies to reduce fractures is unproven. Alternate therapies with fewer data include denosumab, strontium ranelate, teriparatide, oestrogen or testosterone hormone replacement therapy, tibolone, selective oestrogen receptor modulators, and cinacalcet. Parathyroidectomy may be necessary, but is generally avoided within the first post-transplant year. A schema is presented in this chapter that aims to minimize harm when allocating therapy.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!